Searching for a Light at the End of the Tunnel? Beyond Hypomethylating Agents in Myelodysplastic Syndromes
|
Jun 2016
|
Am Soc Clin Oncol Educ Book
|
myelodysplastic syndromes (MDS)
|
Integrating Frailty, Comorbidity, and Quality of Life in the Management of Myelodysplastic Syndromes
|
Jun 2016
|
Am Soc Clin Oncol Educ Book
|
myelodysplastic syndromes (MDS)
|
How I Diagnose Low-Grade Myelodysplastic Syndromes
|
May 2020
|
American Journal of clinical Pathology
|
myelodysplastic syndromes (MDS)
|
Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study
|
Jun 2023
|
American Journal of Hematology
|
aplastic anemia
|
Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study
|
Apr 2023
|
American Journal of Hematology
|
aplastic anemia
|
Myelodysplastic Syndromes: 2021 update on Diagnosis, Risk-stratification and Management
|
Aug 2020
|
American Journal of Hematology
|
myelodysplastic syndromes (MDS)
|
Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes
|
Nov 2019
|
American Journal of Hematology
|
myelodysplastic syndromes (MDS)
|
Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes
|
Jan 2021
|
American Journal of Hematology
|
myelodysplastic syndromes (MDS)
|
Luspatercept use for lower risk myelodysplastic syndromes: Active but not enough
|
Jun 2023
|
American Journal of Hematology
|
myelodysplastic syndromes (MDS)
|
Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management
|
Jun 2023
|
American Journal of Hematology
|
myelodysplastic syndromes (MDS)
|